gemcitabine has been researched along with z-360 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Emori, Y; Eta, R; Hamano, H; Iino, Y; Kawasaki, D; Takei, M; Tanaka, T; Watson, SA; Yoshinaga, K | 1 |
| Borbath, I; Caplin, ME; Coxon, F; Kato, H; Larvin, M; Meyer, T; Nagano, E; Palmer, DH; Peeters, M; Valle, JW; Waters, JS | 1 |
| Hamano, H; Kobayashi, N; Orikawa, Y; Seto, K; Takei, M; Yoshinaga, K | 1 |
| Kato, H; Kobayashi, N; Meyer, T; Seto, K; Takei, M; Yoshinaga, K | 1 |
| Arai, D; Chen, LT; Furuse, J; Ichikawa, W; Ikeda, M; Ioka, T; Ishii, H; Li, CP; Matsuyama, Y; Mizuno, N; Oh, DY; Okusaka, T; Park, YS; Ueno, M; Yamaguchi, T | 1 |
| Hori, Y; Kuki, K; Shiomi, Y; Tanaka, T; Yoshimura, M | 1 |
2 trial(s) available for gemcitabine and z-360
| Article | Year |
|---|---|
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Female; Gastrins; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Receptor, Cholecystokinin B; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2010 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survival Rate | 2017 |
4 other study(ies) available for gemcitabine and z-360
| Article | Year |
|---|---|
Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Gastrins; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Cholecystokinin B; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.
Topics: Animals; Benzodiazepinones; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Benzodiazepinones; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Isoforms; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Receptor, Cholecystokinin B; Signal Transduction; Vascular Endothelial Growth Factor A | 2011 |
Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice
Topics: Animals; Apoptosis; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endopeptidases; Gastrins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survivin; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2017 |